FORM 3

Series B-1 Preferred Stock

(Last)

SUITE 800E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-03

(4)

156,250

 $D^{(1)}$

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 3. Issuer Name and Ticker or Trading Symbol 2. Date of Event 1. Name and Address of Reporting Person* Requiring Statement <u>Denali Therapeutics Inc.</u> [DNLI] Flagship Ventures Fund V, L.P. (Month/Day/Year) 12/07/2017 4. Relationship of Reporting Person(s) to Issuer 5. If Amendment, Date of Original Filed (Last) (First) (Middle) (Check all applicable) (Month/Day/Year) 55 CAMBRIDGE PARKWAY Director 10% Owner SUITE 800E Officer (give title Other (specify 6. Individual or Joint/Group Filing (Check below) below) Applicable Line) Form filed by One Reporting Person (Street) Form filed by More than One CAMBRIDGE MA 02142 Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 1. Title of Security (Instr. 4) 2. Amount of Securities 3. Ownership 4. Nature of Indirect Beneficial Ownership Beneficially Owned (Instr. 4) Form: Direct (D) or Indirect (I) (Instr. 5) 312,500 $D^{(1)}$ Common Stock Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 3. Title and Amount of Securities 1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and 6. Nature of Indirect Expiration Date (Month/Day/Year) Underlying Derivative Security (Instr. 4) Conversion Ownership Beneficial Ownership or Exercise Form: (Instr. 5) Direct (D) Price of Amount or Derivative or Indirect Date Expiration Number of Security (I) (Instr. 5) Exercisable Date Title **Shares** Series A-1 Preferred Stock (2) (2) Common Stock 8,324,999 (2) $D^{(1)}$ Series A-2 Preferred Stock (3) (3) (3) $D^{(1)}$ Common Stock 125,000

Common Stock

1. Name and Address of Reporting Person* Flagship Ventures Fund V, L.P.			
(Last)	(First)	(Middle)	
55 CAMBRIDGE PARKWAY			
SUITE 800E			
(Street) CAMBRIDGE	MA	02142	
(City)	(State)	(Zip)	
1. Name and Address of Reporting Person* AFEYAN NOUBAR			
(Last)	(First)	(Middle)	
55 CAMBRIDGE PARKWAY			
SUITE 800E			
(Street) CAMBRIDGE	MA	02142	
(City)	(State)	(Zip)	
Name and Address of Reporting Person* Flagship Ventures Fund V General Partner LLC			

(First)

55 CAMBRIDGE PARKWAY

(Middle)

(4)

(4)

(Street) CAMBRIDGE	MA	02142
(City)	(State)	(Zip)

Explanation of Responses:

- 1. Held by Flagship Ventures Fund V, L.P. ("Flagship V"). Flagship V"). Flagship Ventures Fund V General Partner LLC ("Flagship V LLC") is the general partner of Flagship V. Noubar B. Afeyan, Ph.D. is the manager of Flagship V LLC. Flagship V LLC and Dr. Afeyan may be deemed to possess voting and investment control over all shares held by Flagship V. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.
- 2. The Series A-1 Preferred Stock shall automatically convert into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date
- 3. The Series A-2 Preferred Stock shall automatically convert into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.
- 4. The Series B-1 Preferred Stock shall automatically convert into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.

Remarks:

Flagship Ventures Fund V, L.P.
By: Flagship Ventures Fund V
General Partner LLC By:/s/
Noubar Afeyan Name: Noubar
B. Afeyan, Ph.D. Title:
Manager
/s/ Noubar B. Afeyan, Ph.D.
Flagship Ventures Fund V
General Partner LLC By:/s/
Noubar Afeyan Name: Noubar
B. Afeyan, Ph.D. Title:
Manager
** Signature of Reporting Person
Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.